Compare ServiceNow Inc (NOW) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ServiceNow Inc vs Recursion Pharmaceuticals Inc — how do they compare? ServiceNow Inc trades at $131.48 (market cap $138.75B), while Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B). The key difference: ServiceNow Inc is far larger — about 74.6× Recursion Pharmaceuticals Inc's market cap, and ServiceNow Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| NOW | RXRX | |
|---|---|---|
Market Cap | $138.75B | $1.86B |
Sector | Technology | Health |
52-Week High | $192.23 | $6.79 |
52-Week Low | $83.00 | $2.84 |
Enterprise Value | $142.54B | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ServiceNow (NOW) trades at $131.11, down 7.19% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew from $7.2B in 2022 to $13.28B in 2025, though net income margin has fluctuated. Positive sentiment is driven by AI integration and conference presentations, while high valuation ratios like a P/E of 83.88 present risks.
The outlook remains positive due to robust revenue growth and AI-driven business expansion, but elevated valuations and competitive pressures warrant caution. Analyst consensus is strongly bullish with a $141.46 price target, though investors should monitor execution risks and macroeconomic headwinds that could impact future performance.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
